Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Morepen Labs successfully raised Rs. 200 Crore through QIP
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated